BR112019001225A2 - composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeo - Google Patents
composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeoInfo
- Publication number
- BR112019001225A2 BR112019001225A2 BR112019001225-7A BR112019001225A BR112019001225A2 BR 112019001225 A2 BR112019001225 A2 BR 112019001225A2 BR 112019001225 A BR112019001225 A BR 112019001225A BR 112019001225 A2 BR112019001225 A2 BR 112019001225A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- polyoxyglyceride
- carboxymethyl cellulose
- polyalkylene glycol
- cholesterol sulfate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 title 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 title 1
- 239000001768 carboxy methyl cellulose Substances 0.000 title 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 title 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 title 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 title 1
- 229920001515 polyalkylene glycol Polymers 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010053159 Organ failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- DTGDZMYNKLTSKC-HKQCOZBKSA-N cholest-5-ene Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 DTGDZMYNKLTSKC-HKQCOZBKSA-N 0.000 abstract 1
- -1 cholesterol sulfates Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229960005489 paracetamol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370200P | 2016-08-02 | 2016-08-02 | |
| US62/370,200 | 2016-08-02 | ||
| US201762470834P | 2017-03-13 | 2017-03-13 | |
| US62/470,834 | 2017-03-13 | ||
| PCT/US2017/044934 WO2018026837A1 (en) | 2016-08-02 | 2017-08-01 | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019001225A2 true BR112019001225A2 (pt) | 2019-04-30 |
Family
ID=61074228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019001225-7A BR112019001225A2 (pt) | 2016-08-02 | 2017-08-01 | composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeo |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200222430A1 (enExample) |
| EP (1) | EP3493810A4 (enExample) |
| JP (2) | JP7048576B2 (enExample) |
| KR (1) | KR102462275B1 (enExample) |
| CN (1) | CN109922811B (enExample) |
| AU (1) | AU2017305305A1 (enExample) |
| BR (1) | BR112019001225A2 (enExample) |
| CA (1) | CA3031215A1 (enExample) |
| IL (1) | IL264391A (enExample) |
| MX (1) | MX391441B (enExample) |
| TW (1) | TW201818946A (enExample) |
| WO (1) | WO2018026837A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| WO2021005399A1 (en) * | 2019-07-08 | 2021-01-14 | The University Of Hong Kong | Compositions and methods for clearing tissue |
| JP7830313B2 (ja) * | 2019-09-30 | 2026-03-16 | デュレクト コーポレーション | アルコール性肝炎の処置 |
| CN115103591B (zh) * | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3170320A1 (en) * | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
| ES3004508T3 (en) * | 2020-04-15 | 2025-03-12 | Gruenenthal Gmbh | Resiniferatoxin compositions |
| CN115803061A (zh) * | 2020-05-22 | 2023-03-14 | 度勒科特公司 | 非酒精性脂肪性肝炎(nash)的治疗 |
| JP2023527153A (ja) * | 2020-05-22 | 2023-06-27 | デュレクト コーポレーション | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
| US20240425545A1 (en) * | 2021-06-25 | 2024-12-26 | Durect Corporation | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same |
| CN114306350B (zh) * | 2022-01-13 | 2023-01-24 | 四川大学华西医院 | 胆固醇硫酸盐在制备预防脓毒症的药物中的用途 |
| CN114646702B (zh) * | 2022-03-03 | 2023-01-06 | 四川大学华西医院 | 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途 |
| WO2024136884A1 (en) * | 2022-12-23 | 2024-06-27 | Durect Corporation | Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same |
| CN121695995A (zh) * | 2024-09-18 | 2026-03-20 | 深圳翰宇药业股份有限公司 | 一种多肽药物的粉碎方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| IS6633A (is) * | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US20090149434A1 (en) * | 2005-09-29 | 2009-06-11 | Joseph Podolski | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| EP1983972A4 (en) | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CN104220450B (zh) * | 2012-04-12 | 2016-07-06 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) |
| EP2842547A1 (en) * | 2013-08-27 | 2015-03-04 | Freund Pharmatec Ltd. | Improved fenofibrate compositions |
| EA201990684A1 (ru) * | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| WO2016005994A2 (en) * | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| BR112017007025A2 (pt) * | 2014-10-10 | 2017-12-12 | Univ Virginia Commonwealth | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio |
-
2017
- 2017-08-01 WO PCT/US2017/044934 patent/WO2018026837A1/en not_active Ceased
- 2017-08-01 US US16/320,074 patent/US20200222430A1/en not_active Abandoned
- 2017-08-01 JP JP2019505245A patent/JP7048576B2/ja active Active
- 2017-08-01 AU AU2017305305A patent/AU2017305305A1/en not_active Abandoned
- 2017-08-01 MX MX2019001327A patent/MX391441B/es unknown
- 2017-08-01 CA CA3031215A patent/CA3031215A1/en active Pending
- 2017-08-01 TW TW106125937A patent/TW201818946A/zh unknown
- 2017-08-01 KR KR1020197005440A patent/KR102462275B1/ko active Active
- 2017-08-01 BR BR112019001225-7A patent/BR112019001225A2/pt active Search and Examination
- 2017-08-01 EP EP17837553.1A patent/EP3493810A4/en not_active Withdrawn
- 2017-08-01 CN CN201780059521.6A patent/CN109922811B/zh not_active Expired - Fee Related
-
2019
- 2019-01-22 IL IL264391A patent/IL264391A/en unknown
-
2021
- 2021-11-15 US US17/526,493 patent/US20220175798A1/en not_active Abandoned
-
2022
- 2022-03-24 JP JP2022047697A patent/JP2022084831A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX391441B (es) | 2025-03-21 |
| WO2018026837A1 (en) | 2018-02-08 |
| JP2019526542A (ja) | 2019-09-19 |
| US20200222430A1 (en) | 2020-07-16 |
| IL264391A (en) | 2019-02-28 |
| EP3493810A4 (en) | 2020-04-08 |
| MX2019001327A (es) | 2019-07-08 |
| KR102462275B1 (ko) | 2022-11-01 |
| AU2017305305A1 (en) | 2019-02-21 |
| US20220175798A1 (en) | 2022-06-09 |
| CA3031215A1 (en) | 2018-02-08 |
| CN109922811A (zh) | 2019-06-21 |
| TW201818946A (zh) | 2018-06-01 |
| CN109922811B (zh) | 2023-09-19 |
| JP2022084831A (ja) | 2022-06-07 |
| KR20190032529A (ko) | 2019-03-27 |
| JP7048576B2 (ja) | 2022-04-05 |
| EP3493810A1 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391441B (es) | Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido. | |
| MX2022013429A (es) | Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. | |
| SA520420518B1 (ar) | تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ | |
| BR112018013174A2 (pt) | composição e método para crescimento de cabelo | |
| MX2022006206A (es) | Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. | |
| MX2024012899A (es) | Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias | |
| MA51103A (fr) | Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique | |
| BR112015021923A2 (pt) | composições de limpeza contendo uma polieteramina, um polímero removedor de sujeiras e uma carboximetil-celulose | |
| BR112018074979A2 (pt) | composições de limpeza que compreendem enzimas | |
| NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
| EA201691147A1 (ru) | Ионные водные композиции | |
| CL2012000243A1 (es) | Hidrogel que comprende acido hialuronico modificado mediante reaccion con divinilsulfona, y un agente de entrecruzamiento tiol; metodo de preparacion; composicion que lo contiene; su uso. ácido hialuronico modificado; metodo de preparacion; su uso. | |
| PH12019501323A1 (en) | Compositions comprising sulfated polysaccharides | |
| BR112019003015A2 (pt) | composições hemostáticas e métodos de preparo das mesmas | |
| CL2008003549A1 (es) | Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes. | |
| BR112018011859A2 (pt) | uso de composições tendo um conteúdo de 3,3´-metilenobis(2-metiloxazolidina) na remoção de compostos de enxofre a partir de correntes de processo | |
| CO2017004735A2 (es) | Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas | |
| CO2017000030A2 (es) | Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas | |
| BR112018008911A2 (pt) | composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas | |
| BR112017006180A2 (pt) | composições de redução de mau odor | |
| MX392710B (es) | Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. | |
| UY36157A (es) | Composiciones pesticidas y procedimientos relacionados con las mismas | |
| EA201890638A1 (ru) | Отклоняющие кислоты, содержащие водорастворимое замедляющее действие средство, а также способы изготовления и применения | |
| AR113134A1 (es) | Arni variante | |
| BR112018074823A2 (pt) | formulações de óxido de polialquileno asparaginase e métodos de fabricação e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |